Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
May 23, 2024 09:50 ET
|
Apnimed, Inc.
Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
May 22, 2024 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected...
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
May 22, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in...
mHealth Services (Monitoring, Diagnosis) Market Trends Analysis Report 2024-2030 Featuring Apple, Google, AirStrip, Samsung, Veradigm, Qualcomm, Vodafone, AT&T, Telefonica, SoftServe, Orange
May 21, 2024 09:36 ET
|
Research and Markets
Dublin, May 21, 2024 (GLOBE NEWSWIRE) -- The "mHealth Services Market Size, Share & Trends Analysis Report By Services (Monitoring Services, Diagnosis Services), By Participants, By Application,...
Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
May 16, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 16, 2024 (GLOBE NEWSWIRE) -- Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight...
ENT and Allergy Associates Reinforces Its Commitment to Future Growth by Welcoming Eight New Specialists in 2024
May 16, 2024 05:00 ET
|
ENT & Allergy Associates
Tarrytown, New York, May 16, 2024 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is excited to welcome eight highly-skilled physicians to their team throughout Summer and Fall of 2024....
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
May 15, 2024 16:05 ET
|
Athira Pharma, Inc.
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024 07:00 ET
|
Acumen Pharmaceuticals, Inc.
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024Initiation of a Phase 1 study to support a...
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 06:03 ET
|
Fennec Pharmaceuticals Inc.
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement...
VITAS® Healthcare Names Four Leaders to Its Executive Team: Melad, Escueta, Dr. Loftis, Durkin
May 13, 2024 07:42 ET
|
VITAS Healthcare
Following several recent promotions announced by the national hospice provider, four new leaders join VITAS Healthcare's executive team.